Denmark · Delayed Price · Currency is DKK Embla Medical Statistics
Total Valuation
Embla Medical has a market cap or net worth of DKK 11.29 billion. The enterprise value is 14.05 billion.
| Market Cap | 11.29B |
| Enterprise Value | 14.05B |
Important Dates
The last earnings date was Tuesday, October 20, 2026.
| Earnings Date | Oct 20, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Embla Medical has 425.25 million shares outstanding. The number of shares has decreased by -0.18% in one year.
| Current Share Class | 425.39M |
| Shares Outstanding | 425.25M |
| Shares Change (YoY) | -0.18% |
| Shares Change (QoQ) | -0.33% |
| Owned by Insiders (%) | 0.08% |
| Owned by Institutions (%) | 71.88% |
| Float | 156.06M |
Valuation Ratios
The trailing PE ratio is 18.32 and the forward PE ratio is 15.74. Embla Medical's PEG ratio is 1.00.
| PE Ratio | 18.32 |
| Forward PE | 15.74 |
| PS Ratio | 1.72 |
| PB Ratio | 1.81 |
| P/TBV Ratio | 80.34 |
| P/FCF Ratio | 14.00 |
| P/OCF Ratio | 12.80 |
| PEG Ratio | 1.00 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.08, with an EV/FCF ratio of 17.42.
| EV / Earnings | 22.66 |
| EV / Sales | 2.14 |
| EV / EBITDA | 11.08 |
| EV / EBIT | 15.27 |
| EV / FCF | 17.42 |
Financial Position
The company has a current ratio of 1.28, with a Debt / Equity ratio of 0.52.
| Current Ratio | 1.28 |
| Quick Ratio | 0.64 |
| Debt / Equity | 0.52 |
| Debt / EBITDA | 2.61 |
| Debt / FCF | 4.00 |
| Interest Coverage | 7.36 |
Financial Efficiency
Return on equity (ROE) is 10.40% and return on invested capital (ROIC) is 7.68%.
| Return on Equity (ROE) | 10.40% |
| Return on Assets (ROA) | 4.94% |
| Return on Invested Capital (ROIC) | 7.68% |
| Return on Capital Employed (ROCE) | 10.05% |
| Weighted Average Cost of Capital (WACC) | 5.92% |
| Revenue Per Employee | 1.46M |
| Profits Per Employee | 137,783 |
| Employee Count | 4,500 |
| Asset Turnover | 0.58 |
| Inventory Turnover | 2.27 |
Taxes
In the past 12 months, Embla Medical has paid 181.94 million in taxes.
| Income Tax | 181.94M |
| Effective Tax Rate | 22.61% |
Stock Price Statistics
The stock price has decreased by -20.51% in the last 52 weeks. The beta is 0.46, so Embla Medical's price volatility has been lower than the market average.
| Beta (5Y) | 0.46 |
| 52-Week Price Change | -20.51% |
| 50-Day Moving Average | 27.92 |
| 200-Day Moving Average | 28.24 |
| Relative Strength Index (RSI) | 41.54 |
| Average Volume (20 Days) | 51,846 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Embla Medical had revenue of DKK 6.56 billion and earned 620.02 million in profits. Earnings per share was 1.45.
| Revenue | 6.56B |
| Gross Profit | 4.08B |
| Operating Income | 889.64M |
| Pretax Income | 804.56M |
| Net Income | 620.02M |
| EBITDA | 1.04B |
| EBIT | 889.64M |
| Earnings Per Share (EPS) | 1.45 |
Balance Sheet
The company has 500.18 million in cash and 3.23 billion in debt, with a net cash position of -2.73 billion or -6.41 per share.
| Cash & Cash Equivalents | 500.18M |
| Total Debt | 3.23B |
| Net Cash | -2.73B |
| Net Cash Per Share | -6.41 |
| Equity (Book Value) | 6.25B |
| Book Value Per Share | 14.63 |
| Working Capital | 648.31M |
Cash Flow
In the last 12 months, operating cash flow was 881.76 million and capital expenditures -75.19 million, giving a free cash flow of 806.58 million.
| Operating Cash Flow | 881.76M |
| Capital Expenditures | -75.19M |
| Depreciation & Amortization | 154.92M |
| Net Borrowing | -584.28M |
| Free Cash Flow | 806.58M |
| FCF Per Share | 1.90 |
Margins
Gross margin is 62.20%, with operating and profit margins of 13.56% and 9.45%.
| Gross Margin | 62.20% |
| Operating Margin | 13.56% |
| Pretax Margin | 12.26% |
| Profit Margin | 9.45% |
| EBITDA Margin | 15.88% |
| EBIT Margin | 13.56% |
| FCF Margin | 12.12% |
Dividends & Yields
Embla Medical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 0.18% |
| Shareholder Yield | 0.18% |
| Earnings Yield | 5.46% |
| FCF Yield | 7.14% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Embla Medical is 31.90, which is 20.15% higher than the current price. The consensus rating is "Buy".
| Price Target | 31.90 |
| Price Target Difference | 20.15% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 7.97% |
| EPS Growth Forecast (3Y) | 17.08% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Embla Medical has an Altman Z-Score of 3.26 and a Piotroski F-Score of 6.
| Altman Z-Score | 3.26 |
| Piotroski F-Score | 6 |